Ron Cohen insider trades: Acorda Therapeutics (ACOR) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ron reports to the SEC
Open-market buys and sales
46 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 17, 2023 | ACOR | ↑ Buy | 20,156 | $0.62 | $13K | Direct | Mar 20, 2023 (3d) |
| Mar 17, 2022 | ACOR | ↓ Sell | 2,289 | $1.70 | $4K | Direct | Mar 21, 2022 (4d) |
| Dec 2, 2019 | ACOR | ↓ Sell10b5-1 | 4,699 | $1.60 | $8K | Direct | Dec 4, 2019 (2d) |
| Dec 3, 2018 | ACOR | ↓ Sell10b5-1 | 3,620 | $20.60 | $75K | Direct | Dec 6, 2018 (3d) |
| Jun 16, 2017 | ACOR | ↑ Buy | 20,000 | $16.95 | $339K | Direct | Jun 20, 2017 (4d) |
| Dec 14, 2016 | ACOR | ↓ Sell10b5-1 | 40,172 | $20.75 | $834K | Direct | Dec 16, 2016 (2d) |
| Dec 1, 2016 | ACOR | ↓ Sell10b5-1 | 7,160 | $20.74 | $148K | Direct | Dec 5, 2016 (4d) |
| Dec 1, 2015 | ACOR | ↓ Sell10b5-1 | 11,850 | $38.08 | $451K | Direct | Dec 3, 2015 (2d) |
| Oct 5, 2015 | ACOR | ↓ Sell10b5-1 | 135,000 | $28.03 | $3.8M | Direct | Oct 6, 2015 (1d) |
| Dec 1, 2014 | ACOR | ↓ Sell10b5-1 | 34,394 | $35.59 | $1.2M | Direct | Dec 3, 2014 (2d) |
| Dec 2, 2013 | ACOR | ↓ Sell10b5-1 | 18,125 | $33.52 | $607K | Direct | Dec 4, 2013 (2d) |
| Aug 20, 2013 | ACOR | ↓ Sell10b5-1 | 149,000 | $34.10 | $5.1M | Direct | Aug 20, 2013 (0d) |
| Jun 10, 2013 | ACOR | ↓ Sell10b5-1 | 11,000 | $34.15 | $376K | Direct | Jun 12, 2013 (2d) |
| Dec 3, 2012 | ACOR | ↓ Sell10b5-1 | 16,407 | $24.22 | $397K | Direct | Dec 5, 2012 (2d) |
| Dec 1, 2011 | ACOR | ↓ Sell10b5-1 | 16,500 | $22.92 | $378K | Direct | Dec 5, 2011 (4d) |
| Jun 8, 2011 | ACOR | ↓ Sell10b5-1 | 12,000 | $30.87 | $370K | Direct | Jun 9, 2011 (1d) |
| May 26, 2011 | ACOR | ↓ Sell10b5-1 | 60,000 | $32.58 | $2.0M | Direct | May 31, 2011 (5d) |
| Apr 18, 2011 | ACOR | ↓ Sell10b5-1 | 60,000 | $28.24 | $1.7M | Direct | Apr 19, 2011 (1d) |
| Dec 1, 2010 | ACOR | ↓ Sell10b5-1 | 15,000 | $26.53 | $398K | Direct | Dec 3, 2010 (2d) |
| Aug 5, 2010 | ACOR | ↓ Sell | 55,000 | $35.93 | $2.0M | Direct | Aug 9, 2010 (4d) |
| Mar 9, 2010 | ACOR | ↓ Sell | 38,000 | $33.44 | $1.3M | Direct | Mar 10, 2010 (1d) |
| Dec 1, 2009 | ACOR | ↓ Sell | 8,500 | $24.51 | $208K | Direct | Dec 3, 2009 (2d) |
| Dec 1, 2008 | ACOR | ↓ Sell | 4,000 | $15.89 | $64K | Direct | Dec 3, 2008 (2d) |
| Sep 8, 2008 | ACOR | ↓ Sell | 13,020 | $29.81 | $388K | Direct | Sep 10, 2008 (2d) |
| Sep 8, 2008 | ACOR | ↓ Sell | 11,517 | $29.62 | $341K | Direct | Sep 10, 2008 (2d) |
| Sep 8, 2008 | ACOR | ↓ Sell | 463 | $29.34 | $14K | Direct | Sep 10, 2008 (2d) |
| Jul 8, 2008 | ACOR | ↓ Sell | 13,100 | $31.17 | $408K | Direct | Jul 9, 2008 (1d) |
| Jul 8, 2008 | ACOR | ↓ Sell | 11,900 | $31.37 | $373K | Direct | Jul 9, 2008 (1d) |
| Jun 5, 2008 | ACOR | ↓ Sell | 40,200 | $31.57 | $1.3M | Direct | Jun 9, 2008 (4d) |
| Jun 5, 2008 | ACOR | ↓ Sell | 9,800 | $32.07 | $314K | Direct | Jun 9, 2008 (4d) |
| May 8, 2008 | ACOR | ↓ Sell | 17,632 | $19.58 | $345K | Direct | May 12, 2008 (4d) |
| May 8, 2008 | ACOR | ↓ Sell | 13,800 | $19.95 | $275K | Direct | May 12, 2008 (4d) |
| Mar 10, 2008 | ACOR | ↓ Sell | 5,500 | $18.10 | $100K | Direct | Mar 12, 2008 (2d) |
| Mar 10, 2008 | ACOR | ↓ Sell | 2,600 | $17.57 | $46K | Direct | Mar 12, 2008 (2d) |
| Dec 10, 2007 | ACOR | ↓ Sell | 8,000 | $20.40 | $163K | Direct | Dec 11, 2007 (1d) |
| Sep 10, 2007 | ACOR | ↓ Sell | 8,000 | $16.14 | $129K | Direct | Sep 12, 2007 (2d) |
| Aug 14, 2007 | ACOR | ↓ Sell | 26,000 | $16.96 | $441K | Direct | Aug 14, 2007 (0d) |
| Aug 13, 2007 | ACOR | ↓ Sell | 22,473 | $17.20 | $387K | Direct | Aug 14, 2007 (1d) |
| Aug 13, 2007 | ACOR | ↓ Sell | 3,527 | $16.31 | $58K | Direct | Aug 14, 2007 (1d) |
| Aug 10, 2007 | ACOR | ↓ Sell | 26,000 | $16.99 | $442K | Direct | Aug 13, 2007 (3d) |
| Aug 9, 2007 | ACOR | ↓ Sell | 26,000 | $17.76 | $462K | Direct | Aug 13, 2007 (4d) |
| Dec 1, 2006 | ACOR | ↓ Sell | 7,591 | $18.93 | $144K | Direct | Dec 5, 2006 (4d) |
| Nov 1, 2006 | ACOR | ↓ Sell | 35,980 | $17.23 | $620K | Direct | Nov 3, 2006 (2d) |
| Nov 1, 2006 | ACOR | ↓ Sell | 14,020 | $16.91 | $237K | Direct | Nov 3, 2006 (2d) |
| Oct 16, 2006 | ACOR | ↓ Sell | 28,000 | $16.51 | $462K | Direct | Oct 18, 2006 (2d) |
| Oct 16, 2006 | ACOR | ↓ Sell | 22,000 | $16.24 | $357K | Direct | Oct 18, 2006 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Ron Cohen's insider trades
Ron Cohen is President and CEO at Acorda Therapeutics (ACOR). Since Oct 16, 2006, Ron has reported 2 open-market purchases worth $352K and 44 sales worth $29.1M on SEC Form 4. There have been no open-market trades in the last 12 months.
16 sales (61% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (26 filings), option exercises (16 filings), shares withheld for taxes (4 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACOR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.